CTOs on the Move

Induchem Usa

www.induchem.com

 
Induchem Usa is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.induchem.com
  • 590 Madison Ave Fl 21
    New York, NY USA 10022
  • Phone: 212.521.4304

Executives

Name Title Contact Details

Similar Companies

Verax Biomedical Incorporated

Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Radiology Associates of Hollywood

Radiology Associates of Hollywood is a Hollywood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company`s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.

Theralogix

Theralogix is a Holmes, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eterna Therapeutics

Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.